MEDICAL DEVICE DEVELOPERS HAVE BEEN COMPELLED TO OUTSOURCE THEIR MANUFACTURING OPERATIONS TO CONTRACT SERVICE PROVIDERS

The in-house development of peptide API requires necessary expertise and capabilities, including design, construction and maintenance of a facility which demands significant capital investments. Therefore, several small drug developers and, at times, certain pharma giants as well, have started outsourcing their manufacturing operations to contract service providers.

Over the years, the popularity of biologics has led to an evident shift in the focus of pharmaceutical companies, from traditional interventions towards more complex and advanced pharmacological interventions, such as peptide therapeutics. Since the discovery of insulin, the peptide therapeutics market has evolved significantly. The increasing demand for companies capable of offering manufacturing and, in certain cases, development services to biopharmaceutical players has resulted in the establishment of several CMOs. Most of these contract service providers have profound experience in niche and emerging areas. The innate expertise and availability of the required capabilities and infrastructure enables CMOs to effectively fulfil the requirements of their clients, eliminate costly oversights and, thereby, reduce chances of failure. As pharma companies resume full-scale operation after the COVID-19 outbreak, the demand for large-scale peptide therapeutics contract API manufacturing is expected to increase significantly.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/305/request-

In fact, drug developers are actively collaborating with CMOs that offer improved technology platforms to increase the bioavailability of peptide drugs and enhance the efficacy of the production process. The aforementioned factors are likely to drive growth of the contract manufacturing and provide lucrative opportunities to CMOs in the near future. Presently, XX% of the total capacity is available with contract manufacturers catering to the needs for commercial scale operations. Further, majority (XX%) of the peptide API contract manufacturing capacity is installed in facilities based in Europe. However, we believe that, in order to cope up with the increasing demand and maintain a competitive advantage, CMOs should further enhance their existing capabilities and capacities, as well as adopt innovative and efficient production technologies.

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

The single-use upstream bioprocessing technology market is projected to grow at a CAGR of 12% till 2035, claims Roots Analysis

Given the various benefits of single-use technology and the rising demand for biologics, the biopharmaceutical industry is gradually shifting from conventional manufacturing equipment to single-use upstream bioprocessing systems.

Roots Analysis has announced the addition of “Single-use Upstream Bioprocessing Market, 2022-2035” report to its list of offerings.

The report features an extensive study on the extensive study of the current landscape and the likely future potential of container closure integrity testing services, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:
● A detailed assessment of the overall market landscape of single-use bioreactors based on a number of relevant parameters, such as scale of operation, type of cell culture system, type of cell culture, type of molecule, key features, application area and end users. In addition, it presents details of the companies developing single-use bioreactors, highlighting their year of establishment, company size, and geographical presence.
● A detailed assessment of the overall market landscape of single-use mixers based on a number of relevant parameters, such as scale of operation, type of mixing system, type of molecule, key features and application area. In addition, it presents details of the companies developing single-use bioreactors, highlighting their year of establishment, company size, and geographical presence.
● A detailed assessment of the overall market landscape of single-use sensors, based on several relevant parameters, such as type of sensor, type of bioprocessing, measurement range, operating temperature, sterilization technique, material used and application area. In addition, the chapter presents details of the companies involved in the development of single-use sensors, including information on their year of establishment, company size, and geographical presence.
● A tabulated section presenting the overall market landscape of other single-use technologies, such as media bags and containers, filters, sampling systems and connectors.
● A detailed competitiveness analysis of single-use bioreactors, single-use mixers and single-use sensors, taking into consideration several relevant parameters. The parameters include the product applicability and product strength.
● Tabulated profiles of the key players providing single-use upstream bioprocessing technologies, which are headquartered in North America, Europe and Asia-Pacific. Each profile includes an overview of the company, information on the financial performance (if available), service portfolio, product portfolio, recent developments, and an informed future outlook.
● An insightful case study depicting the cost saving potential of single-use upstream bioprocessing technology. It also discusses about the time saving potential associated with the single-use upstream bioprocessing technology.
● An informed estimate on the current and future demand-supply scenario for single-use upstream bioprocessing technologies, for the period 2022-2035.
● More than 1,800 patents related to single-use bioprocessing technology have been filed by various industry and non-industry players; this is indicative of the heightened pace of research and innovation in this field.
For more information, please click on the following link:
https://www.rootsanalysis.com/....reports/single-use-u

Other recent offerings:
1. Targeted protein degradation market, 2022-2035
2. Prefilled Syringes Market (6th Edition), 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com

The combination product services market is anticipated to grow at a CAGR of around 10%, till 2035, claims Roots Analysis

Growing interest for combination products, coupled with the ongoing challenges of combining drug / biologic with a medical device, is anticipated to drive the demand for outsourcing combination products development and testing.

Roots Analysis has announced the addition of “Combination Product Services Market, 2022-2035” report to its list of offerings.

The development of drug-device combination products is a long-drawn-out process that not only requires novel technologies and processes but also a huge amount of capital and expertise. In order to overcome these challenges and enhance overall patient experience, several developers are outsourcing their operations to companies that offer services for testing and validation of combination products.

Key Market Insights

Currently, more than 25 service providers claim to offer services for combination products
The market is dominated by the presence of small (11-50 employees) and mid-sized (51-500 employees) players, who represent over 55% of the contemporary market landscape. Additionally, it is worth noting that majority (81%) of the service providers are based in North America.

Around 70% of the players engaged in this industry offer services for drug delivery device / system
Over 65% of the aforementioned players offer services for product development. Further, 60% of the combination product service providers offer services for prefilled syringes. Notably, over 70% of the total players engaged in this space also offer process development and validation services.

Go / No-Go framework can be used to assist players in the outsourcing decision-making process
The framework enables evaluation of the current capabilities of prefilled syringe combination product developers and aids them to take the crucial decision of outsourcing / in-house development and testing of prefilled syringe combination products based on 5+ parameters.

Expansion activity within this field has grown significantly between 2017 and 2022
Maximum number of expansion initiatives (38%) were undertaken in 2021. It is worth highlighting that majority of the expansions were facility expansions. Notably, over 70% of the expansion initiatives have been undertaken for facilities based in North America.

North America and Europe are anticipated to capture larger share (over 65%) of market by 2035
Growth in this domain is anticipated to be primarily driven by the rising demand of combination products. Players providing performance testing services are anticipated to capture more than 75% of the market by 2035.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/....reports/combination-

The financial opportunity within the Combination Product Services (Focus on Particle Testing, Performance Testing and Product Development) Market has been analyzed across the following segments:
 Type of Device
 Service Focus Area
 Company Size
 Geographical Regions

For additional details, please visit https://www.rootsanalysis.com/....reports/combination- or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Medical Devices Contract Research Organization Market (3rd Edition), 2022-2035
2. Prefilled Syringes Market (6th Edition), 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

The rare kidney disorders market is projected to grow at a CAGR of 17%, during the period 2022-2035, claims Roots Analysis

Considering the rising unmet need associated with rare kidney disorders and the growing adoption of available treatment options, industry stakeholders have made significant investments to enable the development of novel drug candidates targeting this set of rare diseases

London
Roots Analysis has announced the addition of the “Rare Kidney Disorders Market, 2022–2035” report to its list of offerings.

More than 90 candidates targeting rare kidney disorders are currently under clinical investigation, while several novel leads are being evaluated in the early stages of development. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. As more candidates are likely to progress towards the advanced stages of development, we expect the market to witness aggressive growth in the foreseen future.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/....reports/rare-kidney-

Key Market Insights

More than 125 drug candidates targeting rare kidney disorders are currently under development
Over 25 total pipeline candidates are available in the market across various geographical regions. Of these, 43% have been approved for the treatment of cystinosis, Fabry disease and lupus nephritis. Further, majority of the approved / under development drugs (47%) are designed for delivery via oral route.

Over 60 companies are engaged in the development of drugs targeting rare kidney disorders
Since 2006, 27 companies have been established in this domain. Further, around 60% of the developers are large and very large firms. In addition, majority (68%) of the players engaged in the development of drugs against rare kidney disorder are based in North America, primarily in the US.

Partnership activity in domain has increased at an annualized rate of >92%, during 2017-2021
It is worth mentioning that the maximum number of partnerships were inked in 2018 and 2019. Further, product development and commercialization agreements emerged as the most popular type of partnership model adopted by rare kidney disorder targeting drug developers, representing over 25% of the total instances.

USD 3.5+ billion has been invested by both private and public investors, since 2017
The maximum funding amount was raised through venture fundings (26%), debt financing (23%) and private equity (18%), during the period 2017-2021. Interestingly, around 85% of the funding instances were reported by players based in North America.

North America is anticipated to capture over 30% of the global market share in 2035
In the long term, close to 40% of the market revenues are expected to be generated from sales of therapeutics targeting lupus nephritis. Further, therapies designed for delivery via the oral route are expected to occupy a larger share (41%) of the overall market in 2035.

The financial opportunity within the rare kidney disorder market has been analysed across the following segments:

 Type of Molecule
 Route of Administration
 Target Indications
 Key Geographical Regions

For additional details, please visit
https://www.rootsanalysis.com/....reports/rare-kidney-

You may also be interested in the following titles:
1. Cell Therapy Manufacturing Market: Industry Trends and Global Forecasts, 2022-2035
2. CAR-T Cell Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

The biosensors market focused on drug discovery and development is projected to grow at an annualized rate of 9% during the period 2022-2035, claims Roots Analysis

In recent years, the use of biosensors in drug discovery has been on the rise, driven by several technological advancements and the growing demand for inexpensive and effective techniques for analyzing potential drug candidates.

Roots Analysis has announced the addition of “Biosensors Market: Focus on Drug Discovery and Drug Development, 2022 - 2035” report to its list of offerings.

A number of drug developers are already using novel biosensors for various drug discovery applications to address the concerns associated with high rate of failures of drug development programs and requirement of high capital investments. As the adoption of biosensors, specifically for drug discovery, increases amongst innovators in the pharma and biopharma industry, lucrative opportunities are expected to be created for players engaged in the biosensors for drug discovery market.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/global-biose

Key Market Insights

Currently, more than 80 biosensors are being developed by various stakeholders, across the world
Majority of the biosensors (64%) engaged in this domain are optical biosensors, followed by electrochemical biosensors (25%), quartz crystal microbalance biosensors (5%) and thermal biosensors (5%). Close to 95% of the biosensors are used for lead identification step in drug discovery. Further, 15% of the biosensors claim to support all the steps in drug discovery.

Over USD 1.2 billion invested in various domain focused initiatives, since 2018
Specifically, in 2021, industry players raised close to USD 600 billion. In addition, majority of the companies (66%) primarily received funding through venture capital rounds. Further, around 60% of the total funding instances were reported by players headquartered in the US.

In recent years, several global events related to biosensors in drug discovery were organized
Majority of the events related to biosensors in drug discovery were organized in Europe (45%). It is worth highlighting that the main agenda of these events was to discuss the development and challenges associated with the biosensors in drug discovery domain.

370+ patents related to biosensors in drug discovery have been granted / filed between 2018-2022
R&D activity related to biosensors in drug discovery is largely concentrated in North America, considering the fact that 70% of the total number of patents were filed in this region. In addition, most of the patents in this domain are granted patents (55%), followed by patent applications (44%).

North America and Europe are anticipated to capture over 70% of the market share, by 2035
In addition, the market in Asia Pacific is likely to grow at a relatively faster pace (10%) in the long term. Further, in 2035, biosensors market for drug discovery applications for academic / research institutes is expected to capture the majority share (~60%) of the total market.


For additional details, please visit
https://www.rootsanalysis.com/....reports/global-biose or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.


Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com